Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females

Silvia Savastano, Carolina Di Somma, Genoveffa Pizza, Annalba De Rosa, Valeria Nedi, Annalisa Rossi, Francesco Orio, Gaetano Lombardi, Annamaria Colao, Giovanni Tarantino

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: Fat mass (FM) in overweight/obese subjects has a primary role in determining low-grade chronic inflammation and, in turn, insulin resistance (IR) and ectopic lipid storage within the liver. Obesity, aging, and FM influence the growth hormone/insulin-like growth factor (IGF)-I axis, and chronic inflammation might reduce IGF-I signaling. Altered IGF-I axis is frequently observed in patients with Hepatic steatosis (HS). We tested the hypothesis that FM, or spleen volume and C-reactive protein (CRP)--all indexes of chronic inflammation--could affect the IGF-I axis status in overweight/obese, independently of HS.Methods: The study population included 48 overweight/obese women (age 41 ± 13 years; BMI: 35.8 ± 5.8 kg/m2; range: 25.3-53.7), who underwent assessment of fasting plasma glucose and insulin, homeostasis model assessment of insulin resistance (HOMA), cholesterol and triglycerides, HDL-cholesterol, transaminases, high-sensitive CRP, uric acid, IGF-I, IGF binding protein (BP)-1, IGFBP-3, and IGF-I/IGFBP-3 ratio. Standard deviation score of IGF-I according to age (zSDS) were also calculated. FM was determined by bioelectrical impedance analysis. HS severity grading (score 0-4 according liver hyperechogenicity) and spleen longitudinal diameter (SLD) were evaluated by ultrasound.Results: Metabolic syndrome (MS) and HS were present in 33% and 85% of subjects, respectively. MS prevalence was 43% in subjects with increased SLD. IGF-I values, but not IGF-I zSDS, and IGF-I/IGFBP-3 ratio were significantly lower, while FM%, FPI, HOMA, ALT, CRP, were significantly higher in patients with severe HS than in those with mild HS. IGF-I zSDS (r = -0.42, r = -0.54, respectively; p <0.05), and IGFBP-1 (r = -0.38, r = -0.42, respectively; p <0.05) correlated negatively with HS severity and FM%. IGF-I/IGFBP-3 ratio correlated negatively with CRP, HS severity, and SLD (r = -0.30, r = -0.33, r = -0.43, respectively; p <0.05). At multivariate analysis the best determinants of IGF-I were FM% (β = -0.49; p = 0.001) and IGFBP-1 (β = -0.32; p = 0.05), while SLD was in the IGF-I/IGFBP-3 ratio (β = -0.43; p = 0.004).Conclusions: The present study suggests that lower IGF-I status in our study population is associated with higher FM, SLD, CRP and more severe HS.

Original languageEnglish
Article number136
JournalJournal of Translational Medicine
Volume9
Issue number1
DOIs
Publication statusPublished - Aug 16 2011

Fingerprint

Somatomedins
Insulin-Like Growth Factor I
Liver
Spleen
Fats
Insulin-Like Growth Factor Binding Protein 3
C-Reactive Protein
Insulin-Like Growth Factor Binding Protein 1
Insulin
Insulin Resistance
Inflammation
Homeostasis
Acoustic impedance
Transaminases
Uric Acid
Electric Impedance
HDL Cholesterol
Population
Growth Hormone
Fasting

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. / Savastano, Silvia; Di Somma, Carolina; Pizza, Genoveffa; De Rosa, Annalba; Nedi, Valeria; Rossi, Annalisa; Orio, Francesco; Lombardi, Gaetano; Colao, Annamaria; Tarantino, Giovanni.

In: Journal of Translational Medicine, Vol. 9, No. 1, 136, 16.08.2011.

Research output: Contribution to journalArticle

Savastano, S, Di Somma, C, Pizza, G, De Rosa, A, Nedi, V, Rossi, A, Orio, F, Lombardi, G, Colao, A & Tarantino, G 2011, 'Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females', Journal of Translational Medicine, vol. 9, no. 1, 136. https://doi.org/10.1186/1479-5876-9-136
Savastano, Silvia ; Di Somma, Carolina ; Pizza, Genoveffa ; De Rosa, Annalba ; Nedi, Valeria ; Rossi, Annalisa ; Orio, Francesco ; Lombardi, Gaetano ; Colao, Annamaria ; Tarantino, Giovanni. / Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. In: Journal of Translational Medicine. 2011 ; Vol. 9, No. 1.
@article{ae45da7ee2cc4437a068ac39238c0dcd,
title = "Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females",
abstract = "Background: Fat mass (FM) in overweight/obese subjects has a primary role in determining low-grade chronic inflammation and, in turn, insulin resistance (IR) and ectopic lipid storage within the liver. Obesity, aging, and FM influence the growth hormone/insulin-like growth factor (IGF)-I axis, and chronic inflammation might reduce IGF-I signaling. Altered IGF-I axis is frequently observed in patients with Hepatic steatosis (HS). We tested the hypothesis that FM, or spleen volume and C-reactive protein (CRP)--all indexes of chronic inflammation--could affect the IGF-I axis status in overweight/obese, independently of HS.Methods: The study population included 48 overweight/obese women (age 41 ± 13 years; BMI: 35.8 ± 5.8 kg/m2; range: 25.3-53.7), who underwent assessment of fasting plasma glucose and insulin, homeostasis model assessment of insulin resistance (HOMA), cholesterol and triglycerides, HDL-cholesterol, transaminases, high-sensitive CRP, uric acid, IGF-I, IGF binding protein (BP)-1, IGFBP-3, and IGF-I/IGFBP-3 ratio. Standard deviation score of IGF-I according to age (zSDS) were also calculated. FM was determined by bioelectrical impedance analysis. HS severity grading (score 0-4 according liver hyperechogenicity) and spleen longitudinal diameter (SLD) were evaluated by ultrasound.Results: Metabolic syndrome (MS) and HS were present in 33{\%} and 85{\%} of subjects, respectively. MS prevalence was 43{\%} in subjects with increased SLD. IGF-I values, but not IGF-I zSDS, and IGF-I/IGFBP-3 ratio were significantly lower, while FM{\%}, FPI, HOMA, ALT, CRP, were significantly higher in patients with severe HS than in those with mild HS. IGF-I zSDS (r = -0.42, r = -0.54, respectively; p <0.05), and IGFBP-1 (r = -0.38, r = -0.42, respectively; p <0.05) correlated negatively with HS severity and FM{\%}. IGF-I/IGFBP-3 ratio correlated negatively with CRP, HS severity, and SLD (r = -0.30, r = -0.33, r = -0.43, respectively; p <0.05). At multivariate analysis the best determinants of IGF-I were FM{\%} (β = -0.49; p = 0.001) and IGFBP-1 (β = -0.32; p = 0.05), while SLD was in the IGF-I/IGFBP-3 ratio (β = -0.43; p = 0.004).Conclusions: The present study suggests that lower IGF-I status in our study population is associated with higher FM, SLD, CRP and more severe HS.",
author = "Silvia Savastano and {Di Somma}, Carolina and Genoveffa Pizza and {De Rosa}, Annalba and Valeria Nedi and Annalisa Rossi and Francesco Orio and Gaetano Lombardi and Annamaria Colao and Giovanni Tarantino",
year = "2011",
month = "8",
day = "16",
doi = "10.1186/1479-5876-9-136",
language = "English",
volume = "9",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females

AU - Savastano, Silvia

AU - Di Somma, Carolina

AU - Pizza, Genoveffa

AU - De Rosa, Annalba

AU - Nedi, Valeria

AU - Rossi, Annalisa

AU - Orio, Francesco

AU - Lombardi, Gaetano

AU - Colao, Annamaria

AU - Tarantino, Giovanni

PY - 2011/8/16

Y1 - 2011/8/16

N2 - Background: Fat mass (FM) in overweight/obese subjects has a primary role in determining low-grade chronic inflammation and, in turn, insulin resistance (IR) and ectopic lipid storage within the liver. Obesity, aging, and FM influence the growth hormone/insulin-like growth factor (IGF)-I axis, and chronic inflammation might reduce IGF-I signaling. Altered IGF-I axis is frequently observed in patients with Hepatic steatosis (HS). We tested the hypothesis that FM, or spleen volume and C-reactive protein (CRP)--all indexes of chronic inflammation--could affect the IGF-I axis status in overweight/obese, independently of HS.Methods: The study population included 48 overweight/obese women (age 41 ± 13 years; BMI: 35.8 ± 5.8 kg/m2; range: 25.3-53.7), who underwent assessment of fasting plasma glucose and insulin, homeostasis model assessment of insulin resistance (HOMA), cholesterol and triglycerides, HDL-cholesterol, transaminases, high-sensitive CRP, uric acid, IGF-I, IGF binding protein (BP)-1, IGFBP-3, and IGF-I/IGFBP-3 ratio. Standard deviation score of IGF-I according to age (zSDS) were also calculated. FM was determined by bioelectrical impedance analysis. HS severity grading (score 0-4 according liver hyperechogenicity) and spleen longitudinal diameter (SLD) were evaluated by ultrasound.Results: Metabolic syndrome (MS) and HS were present in 33% and 85% of subjects, respectively. MS prevalence was 43% in subjects with increased SLD. IGF-I values, but not IGF-I zSDS, and IGF-I/IGFBP-3 ratio were significantly lower, while FM%, FPI, HOMA, ALT, CRP, were significantly higher in patients with severe HS than in those with mild HS. IGF-I zSDS (r = -0.42, r = -0.54, respectively; p <0.05), and IGFBP-1 (r = -0.38, r = -0.42, respectively; p <0.05) correlated negatively with HS severity and FM%. IGF-I/IGFBP-3 ratio correlated negatively with CRP, HS severity, and SLD (r = -0.30, r = -0.33, r = -0.43, respectively; p <0.05). At multivariate analysis the best determinants of IGF-I were FM% (β = -0.49; p = 0.001) and IGFBP-1 (β = -0.32; p = 0.05), while SLD was in the IGF-I/IGFBP-3 ratio (β = -0.43; p = 0.004).Conclusions: The present study suggests that lower IGF-I status in our study population is associated with higher FM, SLD, CRP and more severe HS.

AB - Background: Fat mass (FM) in overweight/obese subjects has a primary role in determining low-grade chronic inflammation and, in turn, insulin resistance (IR) and ectopic lipid storage within the liver. Obesity, aging, and FM influence the growth hormone/insulin-like growth factor (IGF)-I axis, and chronic inflammation might reduce IGF-I signaling. Altered IGF-I axis is frequently observed in patients with Hepatic steatosis (HS). We tested the hypothesis that FM, or spleen volume and C-reactive protein (CRP)--all indexes of chronic inflammation--could affect the IGF-I axis status in overweight/obese, independently of HS.Methods: The study population included 48 overweight/obese women (age 41 ± 13 years; BMI: 35.8 ± 5.8 kg/m2; range: 25.3-53.7), who underwent assessment of fasting plasma glucose and insulin, homeostasis model assessment of insulin resistance (HOMA), cholesterol and triglycerides, HDL-cholesterol, transaminases, high-sensitive CRP, uric acid, IGF-I, IGF binding protein (BP)-1, IGFBP-3, and IGF-I/IGFBP-3 ratio. Standard deviation score of IGF-I according to age (zSDS) were also calculated. FM was determined by bioelectrical impedance analysis. HS severity grading (score 0-4 according liver hyperechogenicity) and spleen longitudinal diameter (SLD) were evaluated by ultrasound.Results: Metabolic syndrome (MS) and HS were present in 33% and 85% of subjects, respectively. MS prevalence was 43% in subjects with increased SLD. IGF-I values, but not IGF-I zSDS, and IGF-I/IGFBP-3 ratio were significantly lower, while FM%, FPI, HOMA, ALT, CRP, were significantly higher in patients with severe HS than in those with mild HS. IGF-I zSDS (r = -0.42, r = -0.54, respectively; p <0.05), and IGFBP-1 (r = -0.38, r = -0.42, respectively; p <0.05) correlated negatively with HS severity and FM%. IGF-I/IGFBP-3 ratio correlated negatively with CRP, HS severity, and SLD (r = -0.30, r = -0.33, r = -0.43, respectively; p <0.05). At multivariate analysis the best determinants of IGF-I were FM% (β = -0.49; p = 0.001) and IGFBP-1 (β = -0.32; p = 0.05), while SLD was in the IGF-I/IGFBP-3 ratio (β = -0.43; p = 0.004).Conclusions: The present study suggests that lower IGF-I status in our study population is associated with higher FM, SLD, CRP and more severe HS.

UR - http://www.scopus.com/inward/record.url?scp=80051615349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051615349&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-9-136

DO - 10.1186/1479-5876-9-136

M3 - Article

C2 - 21846339

AN - SCOPUS:80051615349

VL - 9

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 136

ER -